Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (371-380 of 609) with videos related to

Pageof 61
Sort By:
Journal of the American Academy of Dermatology|October 9, 2009
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis FoundationAmylynne J Frankel, Abby S Van Voorhees, Sylvia Hsu, et al.
Journal of Molecular Endocrinology|August 30, 2002
Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activityL K Beitel, Y A Elhaji, R Lumbroso, et al.
Journal of the American Academy of Dermatology|October 1, 1995
Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic studyS L Gottlieb, N S Heftler, P Gilleaudeau, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Lancet (London, England)|June 13, 2018
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyAtul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, et al.
Dermatology (Basel, Switzerland)|May 22, 2019
Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM)Nicole Salame, Josefina Torres, Jeena Sandhu, et al.
Journal of the American Academy of Dermatology|September 25, 2004
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialAlice B Gottlieb, Robert Evans, Shu Li, et al.
The Journal of Investigative Dermatology. Symposium Proceedings|May 16, 2007
Structural-functional relationships of TNF-alpha antagonists: next stepsFrank J Dann, Alice B Gottlieb, George S Deepe, et al.
Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2012
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasisR G Langley, K Papp, A B Gottlieb, et al.
Pageof 61

Showing results (371-380 of 609) with videos related to

Sort By:
Pageof 61
Journal of the American Academy of Dermatology|October 9, 2009
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis FoundationAmylynne J Frankel, Abby S Van Voorhees, Sylvia Hsu, et al.
Journal of Molecular Endocrinology|August 30, 2002
Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activityL K Beitel, Y A Elhaji, R Lumbroso, et al.
Journal of the American Academy of Dermatology|October 1, 1995
Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic studyS L Gottlieb, N S Heftler, P Gilleaudeau, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Lancet (London, England)|June 13, 2018
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyAtul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, et al.
Dermatology (Basel, Switzerland)|May 22, 2019
Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM)Nicole Salame, Josefina Torres, Jeena Sandhu, et al.
Journal of the American Academy of Dermatology|September 25, 2004
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialAlice B Gottlieb, Robert Evans, Shu Li, et al.
The Journal of Investigative Dermatology. Symposium Proceedings|May 16, 2007
Structural-functional relationships of TNF-alpha antagonists: next stepsFrank J Dann, Alice B Gottlieb, George S Deepe, et al.
Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2012
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasisR G Langley, K Papp, A B Gottlieb, et al.
Pageof 61